Saudi Arabia Plasma Fractionation Market Size, Demand Drivers and Strategic Outlook 2025–2033

Saudi Arabia Plasma Fractionation Market Overview

Market Size in 2024: USD 322.2 Million

Market Size in 2033: USD 728.5 Million

Market Growth Rate 2025-2033: 8.5%

According to IMARC Group’s latest research publication, “Saudi Arabia Plasma Fractionation Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033”, The Saudi Arabia plasma fractionation market size was valued at USD 322.2 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 728.5 Million by 2033, exhibiting a CAGR of 8.5% during 2025-2033.

How AI is Reshaping the Future of Saudi Arabia Plasma Fractionation Market

• AI-driven process optimization enhances plasma protein purification efficiency in Saudi Arabia, improving yield quality and reducing production costs through real-time parameter adjustments during fractionation.
• Machine learning algorithms predict optimal fractionation conditions by analyzing historical data patterns, enabling manufacturers to achieve consistent product quality and minimize batch-to-batch variability across facilities.
• Predictive analytics monitor equipment performance continuously, detecting potential failures before they occur and scheduling preventive maintenance to reduce downtime and extend operational lifespan of fractionation systems.
• AI-powered quality control systems automate testing procedures for immunoglobulins and albumin, ensuring regulatory compliance and accelerating release times while maintaining stringent safety standards throughout production.
• Smart supply chain management leverages AI forecasting to optimize plasma collection, storage, and distribution, reducing waste and ensuring sufficient inventory levels to meet Saudi healthcare demands efficiently.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-plasma-fractionation-market/requestsample

How Vision 2030 is Transforming Saudi Arabia Plasma Fractionation Industry

Saudi Arabia’s Vision 2030 is revolutionizing the plasma fractionation industry by prioritizing healthcare self-sufficiency, biotechnology advancement, and pharmaceutical manufacturing capabilities amid growing demand for plasma-derived therapies. The initiative drives investment in local fractionation facilities and plasma collection infrastructure, integrating cutting-edge technologies to support the Kingdom’s emerging biopharmaceutical sector. This transformation aligns with health security goals, promoting domestic production of immunoglobulins, albumin, and clotting factors to reduce import dependence and ensure sustainable supply of life-saving treatments. Government partnerships with international pharmaceutical companies bring global expertise and technology transfer to Saudi facilities, while investments in biomedical research create pathways for innovation in plasma processing methods. Vision 2030’s emphasis on biotechnology development positions the Kingdom as a regional manufacturing hub, with the Ministry of Health leading transformation through integrated health systems and the launch of the Biotech Accelerator in partnership with BioLabs. Ultimately, Vision 2030 elevates the plasma fractionation sector as part of broader pharmaceutical localization efforts, supporting the healthcare needs of a growing population and positioning Saudi Arabia as a leader in biotherapeutic manufacturing and plasma-derived medicine development.

Saudi Arabia Plasma Fractionation Market Trends & Drivers:

Saudi Arabia’s plasma fractionation market is experiencing robust growth, driven by rising aging population requiring immunotherapy treatments and plasma-based therapies for age-related conditions. By 2030, it is projected that over 11% of the Saudi population will be aged 60 and above, creating substantial demand for immunoglobulin treatments, albumin, and clotting factors. Older individuals often have weaker immune systems, making them more susceptible to infections and requiring consistent medical care through plasma-derived products. The healthcare system is focusing on addressing the requirements of the senior population, leading to better access and greater demand for specialized treatments. Additionally, elderly patients are more prone to surgeries and hospitalizations, which further creates the need for plasma-based items like albumin and clotting factors essential for recovery and maintaining health.

The increasing prevalence of chronic diseases is significantly boosting market demand. Conditions such as hemophilia, primary immunodeficiency disorders, liver cirrhosis, and autoimmune diseases require plasma-derived therapies for effective management. According to a research study conducted in the dermatology clinic of King Abdulaziz Medical City, Riyadh, Saudi Arabia, as of May 2024, a total of 839 cases of autoimmune diseases were analyzed, with women making up 56.4% of the participants. The most prevalent autoimmune condition was hypothyroidism, followed by alopecia areata and atopic dermatitis. Plasma-based products like clotting factors, immunoglobulins, and albumin are essential in treating patients suffering from chronic and life-threatening illnesses. Healthcare providers in Saudi Arabia continue to rely on these items to offer better therapeutic outcomes, especially as awareness and diagnosis rates are improving. The government is supporting initiatives that enhance healthcare infrastructure and access to specialized treatments, while the Kingdom witnesses a rise in surgical procedures and trauma cases, creating greater need for albumin and clotting factors.

Saudi Arabia Plasma Fractionation Market Industry Segmentation:

The report has segmented the market into the following categories:

Product Insights:

• Immunoglobulins
• Albumin
• Coagulation Factor VIII
• Coagulation Factor IX

Sector Insights:

• Private Sector
• Public Sector

Application Insights:

• Neurology
• Immunology
• Hematology
• Others

End User Insights:

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

Breakup by Region:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in Saudi Arabia Plasma Fractionation Market

• June 2025: Saudi Arabia celebrated World Blood Donor Day with the Ministry of Health highlighting that Saudis ranked first globally out of 28 countries in terms of demand for blood donation, demonstrating strong national commitment to supporting plasma collection and transfusion services aligned with Vision 2030 healthcare goals.
• July 2025: The Saudi Ministry of Health showcased biotechnology advancements at BIO International Convention in Boston, highlighting genome research, health-focused AI, gene therapy development, and vaccine localization, while launching the Biotech Accelerator in partnership with BioLabs supporting innovative Saudi biotech startups in plasma-derived therapeutics.
• August 2025: Saudi Arabia launched the annual Crown Prince’s Blood Donation Campaign, supported by 185 accredited blood donation centers nationwide with electronic booking through the Sehhaty application, promoting voluntary blood donation culture and sustainable plasma supply to build vibrant, healthy society under Vision 2030 framework.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302